The company has secured regulatory approval to sell its hip product portfolio in China and has signed an exclusive distribution deal with China’s largest domestic orthopaedic producer, AK Medical.
The Chapeltown firm expects to sell a minimum of 10,000 hip implants in China over the next five years.
Keith Jackson, JRI Orthopaedics chief executive, said: “China has a population of 1.3 billion but currently only 250 million people have access to a hip replacement. The potential is huge and we see this as a significant market for the company.
“There is a really good appetite for high-quality, innovative British brands. Our proven, world class, precision manufacturing capabilities and efficiencies means we have defied convention to manufacture Chinese-designed products for the Chinese market here in Sheffield.
“But, securing regulatory approval from the Chinese Food and Drink Administration to sell our own high-quality products to Chinese orthopaedic surgeons is a huge step.”
Last year, JRI secured a major £4m sub-manufacturing contract with AK Medical. The three-year deal means Chinese designed hip implants are being manufactured in JRI’s Sheffield plant for sale in China.
A further order has been secured which will increase the number of AK Medical implants manufactured in Sheffield next year by 50%.
JRI Orthopaedics, which employs 115 people, is planning further market expansion in Asia and the Far East. It is submitting product registrations in Japan and, after signing a distribution deal, is hoping to get regulatory approvals there by the end of 2017.